MMDA-2, also known as 2-methoxy-4,5-methylenedioxyamphetamine or as 6-methoxy-MDA, is a psychedelic drug, psychedelic drug of the substituted amphetamine, amphetamine class. It is closely related to 3-methoxy-4,5-methylenedioxyamphetamine, MMDA and 3,4-Methylenedioxyamphetamine, MDA. Alexander Shulgin was likely the first to chemical synthesis, synthesize MMDA-2. In his book ''PiHKAL'', the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours. Shulgin reports that MMDA-2 produces effects such as enhanced awareness, empathy, and mental imagery, visual facilitation and visual distortion, distortion, as well as some side effects like abdominal pain, gastrointestinal upset and appetite loss. He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose. Scientific research has shown that MMDA-2, unlike MMDA, but similarly to 6-methyl-MDA, is only very weak at inducing the release of serotonin or dopamine, and accordingly, does not produce amphetamine-like responses in animals in drug discrimination studies. Instead, MMDA-2 is likely to act as a pure serotonin 5-HT2 receptor, 5-HT₂ receptor agonist similarly to the DOx series of compounds, with activation of the serotonin 5-HT2A receptor, 5-HT_2A receptor conferring its psychedelic effects. MMDA-2 has been sold as a designer drug in Japan.

References

External links

Erowid - PiHKAL entry for MMDA-2

Isomerdesign - PiHKAL entry for MMDA-2
{{Phenethylamines Designer drugs Entactogens Methoxyphenethylamines Methylenedioxyphenethylamines Phenol ethers Psychedelic phenethylamines Serotonin receptor agonists Substituted amphetamines

See also

References

External links